Pluripotent stem cells (PSCs) can form any specialized cell type found in the body making them an excellent tool for regenerative medicine applications. Directed differentiation of PSCs into specific phenotypes can be accomplished by introducing specific chemical cues such as the small molecule retinoic acid (RA). Expressed in the developing nervous system, RA can induce differentiation of PSCs into neural phenotypes including neurons. In this study, we encapsulated all-trans RA within poly (ɛ-caprolactone) (PCL) microspheres to generate controlled morphogen release over 28 days. RA/PCL microspheres less than ~10 µm in diameter were readily incorporated within the interstitial sites of human induced pluripotent stem cell (hiPSC) aggregates. After 5 days of culture, the microspheres did not induce cytotoxic effects and the hiPSC aggregates containing microspheres showed a decrease in the pluripotency marker SSEA-4. After 7 days of culture on laminin surfaces, aggregates expressed the neuronal marker TUJ1 and displayed extended neurite outgrowth. This approach provides consistent RA delivery throughout the aggregate and could be an effective strategy for differentiating cells in vivo.
Introduction
Pluripotent stem cells (PSCs) are primary cells capable of differentiating into any specialized cell-type found in the body as well as self-renewal, both desirable properties when developing cell therapies. 14, 17, 39, 47 PSCs can be divided into two main categories, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). 6 ESCs are isolated from the inner mass of blastocysts and were first derived from mouse embryos followed by isolation from human embryos. 3, 6, 12, 16, 42 iPSCs are adult somatic cells genetically reprogrammed into an embryonic stem cell-like state. The generation of mouse iPSCs (miPSCs) was first reported in 2006 and quickly followed by the production of human iPSCs (hiPSCs) in 2007. 40 , 41 With this latest discovery, iPSC technology provides an excellent tool for the development of personalized tissues for regenerative medicine applications.
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PSCs are often cultured as 3D spheroid aggregates called embryoid bodies (EBs) to induce differentiation. 42 EBs show behavior akin to gastrulation as the PSCs spontaneously differentiate and rearrange into defined germ layers. 43 EB formation serves as an initial assay of PSC pluripotency. It is also the first step in the production of neural progenitor cells (NPCs), cells committed to the neural lineage. EB composition can be altered towards a preferred germ layer by introducing chemical cues or changing the physical properties of the EB. 5, 31, 48, 52 Physical properties include EB size and morphology as well as the number of cells, which can be tailored during the formation process. 13, 36 Additionally, EB-based differentiation could serve as a scalable solution towards mass production of specialized cells. 8 Various chemical cues have been shown to influence PSC differentiation into NPCs. 38 Retinoic acid (RA), a small morphogenic molecule, can be used to induce differentiation of ESCs and iPSCs into motor neurons. 4, 29, 34, 35 Morphogens, like RA, are typically administered in solution with culture media where achieving a uniform distribution is important for predictable and consistent differentiation of PSC aggregates. A model for the diffusion of small molecules such as RA into the interior of EBs suggests that cell consumption rates, aggregate diameter, and cell density are important factors during PSC differentiation. 44 High consumption rates can lead to low concentrations within the aggregate, which in turn can result in nonhomogeneous differentiation. 25, 37, 44 Morphological differences have been observed in mouse ESC (mESC)
EBs when diffusion constraints were bypassed through microparticle delivery of small molecules. 9 Furthermore, while the use of soluble factors is convenient for in vitro differentiation, such strategies cannot be readily translated for in vivo applications. For instance, in neurological disorders such as spinal cord injury (SCI), the injury site contains cues that influence stem cell survival and differentiation. Specifically, the acute phase of SCI is characterized by an inflammatory response that protects surviving tissue by forming a cystic cavity surrounded by a glial scar. 19, 49, 53 This inflammatory response severely affects the survival of transplanted NPCs through its secondary injury mechanisms, such as activated macrophages secreting tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) that result in death of host oligodendrocytes. 33, 53 In addition to cues present due to secondary injury, grafted NPCs are also subjected to other inhibitory signals such as chondroitin sulfate proteoglycans (CSPGs) produced by reactive astrocytes that surround the injury site. 49 This harsh environment can cause the differentiation of NPCs into astrocytes, potentially resulting in a painful condition known as allodynia. 20, 26, 45 Thus, it is critical to develop strategies for promoting NPC differentiation that overcome these environmental factors present at the injury site.
To deliver small morphogenic molecules for in vivo applications, these molecules can be encapsulated within biomaterial-based microspheres for sustained release. This approach enables localized delivery of hydrophobic molecules throughout PSC aggregates to promote homogenous differentiation. Other groups have shown that microspheres manufactured from variety of biodegradable polymers can be used to deliver morphogens throughout mESC aggregates. [7] [8] [9] [10] However, the effects of incorporating drug-releasing microspheres into hiPSC aggregates have not been investigated. Moreover, such a strategy has not been used to generate neural tissue by combining hiPSC aggregates with morphogen releasing microspheres.
A number of polymers, such as poly(lactic-co-glycolic acid) (PLGA), have been widely used to produce microspheres due to their biodegradability and low cytotoxicity. 2, 50 However, the mass production of morphogen loaded microspheres from PLGA is prohibitive due to its high cost per milligram. Accordingly, there has been a renewed interest in poly(ɛ-caprolactone) (PCL) as a low cost alternative for fabricating scaffolds and microspheres. 1, 31, 51 PCL has a biodegradation rate that can extend well over a year, a desirable feature for long-term applications. 51 These properties offer a compelling case for using PCL in neural tissue engineering where the differentiation process can take up to 150 days. 21, 39, 46 In this study, we encapsulated different concentrations of RA within PCL microspheres using a single emulsion technique and characterized the resulting size distribution and release of RA over a 28 day time course. Next, PCL microspheres were successfully incorporated into hiPSC aggregates, which remained intact after 5 days of culture with no cytotoxic effects observed. We measured the expression levels of pluripotency marker SSEA-4 in hiPSCmicrosphere aggregates at Day 5. hiPSC aggregates containing RA releasing microsphere had decreased SSEA-4 expression suggesting that the controlled release of RA induced the differentiation of hiPSCs compared to controls. Finally, we showed that after an additional 7 days of culture, these hiPSC-derived aggregates containing RA releasing microspheres could differentiate into neurons. This work shows that PCL microspheres are a viable option for sustained morphogen delivery within hiPSC aggregates.
Materials and methods

Microsphere fabrication and sterilization
Microspheres were fabricated by an oil-water (o/w) single emulsion as previously described. 23 Briefly, 500 mg of poly (ɛ-caprolactone) (PCL) (Mn ~ 45,000; Sigma) were 
Microsphere characterization
The size and surface morphology of microspheres was characterized using a Hitachi S-4800 FE scanning electron microscope (SEM) as previously described. 1 Microspheres were suspended in a small volume of ethanol and dispersed over SEM stubs. After the ethanol evaporated, the stubs were sputter coated with gold-palladium using an Anatech Hummer VI sputter coater. Microsphere diameters were quantified using the Quartz-PCI Image Management Systems® software. The resulting distribution of microsphere diameters was plotted as a histogram with bin sizes equal to 1 µm intervals between the smallest to the largest diameter observed for each batch. A kernel density estimator function from the R statistical programming language was used to estimate the probability density function of each histogram. Polynomial regression was used to best fit the density function. The population mean, or expected microsphere diameter, is the first moment of the density function, and variance is equal to the second central moment of density function.
Characterization of RA release from microspheres
RA concentrations in the microspheres were determined by dissolving 10 mg of 4 and 30 µg/mg microspheres in DCM. The PCL was then precipitated out of solution with 100% ethanol and removed by centrifugation. The light absorbance of the supernatant was measured at 354 nm using an Infinite M200Pro plate reader with the RA concentration being determined using a standard curve. The corresponding encapsulation efficiencies were calculated using the following equation; the recovered RA corresponds to the amount obtained from dissolved microspheres, and the total RA corresponds to the amount initially dissolved in 500 mg of PCL.
[ ( ) ( ) ]
Release studies were performed as follows. 10 mg of 4 and 30 µg/mg microspheres were suspended in 1 ml of phosphate buffer saline (PBS) (Life Technologies) in a conical vial. The vials were then placed on a microplate shaker (VWR Microplate Shaker) and incubated at 37 °C.
The PBS wash was replaced every 2 days. Multiple vials were labeled for retrieval at a predetermined schedule: day 2, 4, 8, 12, 16, 20, 24, and 28. PBS was removed during retrieval and microspheres were washed with distilled water, freeze dried, and weighed. Once dry, microspheres were dissolved in DCM and the PCL was precipitated with 100% ethanol. The solution absorbance was measured at 354 nm and the RA concentration was determined as previously described. The quantity of RA released was calculated by subtracting the RA remaining in the microspheres from the RA present in day 0 microspheres. Figure 1 shows a schematic of the microsphere incorporation into the hiPSC aggregates.
Pluripotent stem cell culture
Undifferentiated mESCs (R1, Nagy Lab) were cultured on feeder layers as previously described. 32 Undifferentiated hiPSCs (iPS(Foreskin)-1, Lot 1-DL-01, WiCell) were maintained on Vitronectin XF™ (STEMCELL Technologies)-coated 6 well plates in TeSR™-E8™ media (STEMCELL Technologies) as previously described. 31 hiPSCs were dissociated using ReLeSR™ (STEMCELL Technologies) and uniform aggregates were formed by adding a single cell suspension of 1x10 6 hiPSCs in AggreWell™ 800 inserts (STEMCELL Technologies).
hiPSC-microsphere aggregates were formed by resuspending 0.5 mg of microspheres in a small volume (<100 µl) of neural induction medium (NIM) (STEMCELL Technologies), added to each AggreWell™ 800 insert, and centrifuged for 5 minutes at 100 x g to deposit the cells and microspheres. hiPSC, and hiPSC-microsphere aggregates were maintained on AggreWell™ 800 inserts in 2 ml of NIM for 5 days with daily media changes. On day 5, aggregates were dislodged by gentle pipetting and transferred to a poly-L-ornithine (PLO)/laminin-coated (Sigma) 24 well plate. 500 nM of RA was added to the media of a positive control group that did not contain microspheres.
Flow cytometry
On day 5, cell viability and SSEA-4 marker expression in hiPSC aggregates were assessed using flow cytometry as previously described. 32 Briefly, aggregates were removed from suspension culture, rinsed twice with PBS, and dissociated enzymatically using 0. 
Immunocytochemistry
On Day 12 of differentiation, hiPSC aggregates were prepared for immunocytochemistry as previously described. 32 Briefly, the aggregates were fixed with 10% formalin (Sigma) for 1 hour at room temperature, permeabilized using 0.1% Triton-X100 (Sigma) in PBS for 45 minutes at 4°C, and blocked using 5% normal goat serum (NGS) for 2 hours at 4 °C. They were then incubated overnight with a 1:500 dilution of TUJ1 primary antibody (anti-III-beta-tubulin; Millipore) followed by three rinses with PBS and a 1:200 dilution of IgG (H+L) secondary antibody (AlexaFluor 488 goat anti-mouse; Life Technologies) for 4 hours at room temperature in the absence of light. Samples were rinsed three times to remove unconjugated secondary antibody and counterstained with DAPI (Invitrogen). Images were made using a Leica DMI3000B inverted microscope, Lumen Dynamics X-Cite® 120Q LED fluorescence light source, and QImaging camera and software.
Quantitative analysis of neural aggregate morphology
Immunostained hiPSC aggregates were imaged with an IncuCyte ZOOM® live-cell imaging system (Essen BioScience, Ann Arbor, MI). Morphological metrics were quantified using the IncuCyte ZOOM® Software (2015A). Masking and analysis of green channel fluorescence (TUJ1 positive) images for neurite length and branch points were done by the NeuroTrack™ software module while EB area analysis was done using a Basic Analyzer processing definition. Quantification of the metrics was calculated from 74 separate images between two wells per treatment group. The resulting data were normalized by the number of aggregates present in each well.
SEM imaging of hiPSC aggregates
The morphology of human cells and the distribution of microspheres within the hiPSC aggregates were analyzed by SEM after 12 days of differentiation. Samples were fixed using each with 30%, 50%, 70%, and 90% ethanol was followed by three 5-minute rinses with 100% ethanol. The samples were then critically point dried, mounted to SEM stubs, and gold-palladium sputter coated before SEM.
Statistical Analysis
RA encapsulation efficiencies are reported as mean ± standard deviation (n = 6). Release studies are reported as mean ± standard error (n = 3). Flow cytometry results are reported as mean ± standard deviation (n = 3). Statistical significance was determined with standard t-test analysis using the R statistical programming language. * indicates p < 0.05.
Results
Microsphere fabrication and characterization
Surface morphology and size distribution were determined to assess microsphere fabrication. SEM images of the microspheres showed a smooth round surface with some clustering [ Fig. 2 (A -C) ]. 4 and 30 µg/mg microspheres are statistically similar in size with expected diameters of 3.59 ± 2.48 µm, and 3.41 ± 1.60 µm respectively, while the unloaded microspheres are slightly smaller with an expected diameter of 2.53 ± 1.65 µm [ Fig. 2 (D -F) ].
Encapsulation efficiencies for the different loading concentrations of RA are shown in Table 1 .
Despite the differences in the quantity of RA encapsulated in each sample group, all microspheres had approximately the same encapsulation efficiency (~60%). Others have reported encapsulation efficiencies with different polymers that are consistent to those reported here (48 -58%). 23 No statistical differences were observed between the encapsulation efficiencies of the two microsphere groups reported here (n = 6).
The release kinetics of RA were performed in triplicate and analyzed over 28 days [ Fig 
Flow cytometry
Flow cytometry of hiPSC aggregates was performed on Day 5 of cell culture to assess cell viability and determine if the controlled release of RA from the microspheres had any effect on cell differentiation. After 5 days, the percent viability of hiPSC and hiPSC-microsphere aggregates remained similar to Day 0 undifferentiated cells [ Fig. 4 (A) ]. The viability studies showed that hiPSC aggregates were not negatively affected by sterilized PCL microspheres.
Similarly, hiPSC-microsphere aggregates remained tightly aggregated after 5 days. This observation is encouraging as it implies that strong aggregate formation is sustainable with PCL microspheres and that the PCL itself is not leading to cell death. Expression of pluripotent marker SSEA-4 significantly decreased in hiPSC-microsphere aggregates containing RA releasing microspheres when compared to Day 0 undifferentiated cells [ Fig. 4 (B) ]. SSEA-4 expression of the negative control and unloaded microspheres groups remained similar to Day 0 levels. The controlled release of RA is likely to be inducing differentiation as the cells were more differentiated than the untreated negative control and unloaded microsphere groups.
Morphology of differentiated cell cultures
By day 5 of cell culture, hiPSC-microsphere aggregates remained spherically uniform and similar to both control groups without microspheres Further SEM analysis of Day 12 hiPSC-unloaded microspheres aggregates showed that the majority of incorporated microspheres were less than 10 µm in diameter, congruent with previously published studies [ Fig. 7 (A, B) ]. 10 
Discussion and future work
In this study, we demonstrated that PCL microsphere-mediated delivery of RA can overcome diffusion barriers of soluble morphogens into 3D hiPSC aggregates. PCL was chosen as an affordable alternative to other polymers and for its potential biocompatibility with cell culture. These features make PCL a suitable polymer for neural tissue engineering applications.
A single emulsion technique was used to produce large quantities of microspheres in a relatively short period of time. The expected diameter analysis of the RA releasing microspheres reported here point towards a reproducible target size. Carpenedo et al. showed that microsphere diameter affects incorporation efficiency within mESC aggregates with smaller diameter microspheres (1 µm) being more readily incorporated within mESC aggregates than larger ones (3 µm). 10 Additionally, the study revealed that incorporated microspheres ranged in size from 2 to 5 µm while larger diameter microspheres (11 µm) were excluded. The microspheres used by When hiPSCs were cultured with 0.5 mg of microspheres, these instabilities were not observed.
However, Rho-association protein kinase (ROCK)-inhibitors have been shown to increase dissociated human PSC survival and may also enhance cell survival in aggregates containing higher quantities of microspheres. Future studies will seek to further optimize the microsphere to cell ratio to produce hiPSC aggregates while providing optimum morphogen delivery to enhance differentiation.
The encapsulation efficiencies of the low-cost PCL microspheres reported here (~60%), are consistent with PLGA microspheres following a similar fabrication. 23 It is possible that during the four-hour solvent evaporation a RA concentration equilibrium between the solvent and water phases may have been reached that prevented further diffusion of RA out of the PCL solution. The release studies show that RA cumulative release percent remained similar until day 24, at which point the higher concentration microspheres released more RA. The SEM analysis at day 12 of incorporated microspheres showed little bulk degradation suggesting that RA release is mostly driven by diffusion. However, it is not known at this time if a higher quantity of RA in microspheres increases the degradation rate of PCL or if, in a longer term release study, the microspheres will begin to break apart and cause a spike in the RA released. Longer release studies would provide further insight into the mechanisms of RA release from PCL and whether the remaining RA would continue to be released gradually as the PCL degrades.
Quantitative viability studies and pluripotency marker expression confirmed that PCL is not cytotoxic to hiPSC aggregates and that microsphere mediated RA delivery lowers 
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